Recce Pharmaceuticals Limited announced the Australian Patent Office issued notification of intent to grant Recce's Patent Family 3 "Anti-Virus Agent and Method for Treatment of Viral Infection"
The Australian Patent claims relating to RECCE« 327 (R327) and Anti-Viral formulation RECCE« 529 (R529), most notably: Composition/method of manufacture of RECCE« anti-infectives, Use of R327 or R529 for the treatment of viruses having a lipid envelope or coat, examples being SARS-CoV-2 and Corona viruses, Influenza viruses, HIV, Hepatitis, Ross River and Herpes viruses, Administration of R327 or R529 by oral, injection, inhalation and transdermal dose applications. This is the final patent of Family 3 (expiry, November 2037), following those already granted in the biggest pharmaceutical markets in the world such as China, Japan, Europe and Hong Kong.